Germany-based chemical company BASF has signed an agreement with Bend Research to jointly evaluate and develop novel excipients to improve the solubility and bioavailability of poorly soluble drugs.
As part of the agreement, both the companies will combine their expertise in the development of new excipients and drug formulations to provide customers from the pharmaceutical industry with early access to the latest polymer innovations.
The collaboration aims to meet increasing challenges of poorly soluble active pharmaceutical ingredients BCS Class II and IV compounds.
The initial focus will be on optimizing new vinylpyrrolidone based copolymers being developed for the solubilization of poorly soluble active pharmaceutical ingredients.
Bend Research CEO Rod Ray said the new collaboration will offer early access to a different set of chemistries and allows the firms to develop and test customer formulations based on new polymers.
"BASF has an impressive track record developing and launching novel excipients. This deal complements our recently announced collaboration on cellulosics, because it gives us access to completely different chemistries," Ray added.
